Skip to content

Study · Not a test of the peptide alone · 2004

2 results

Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.

Cavasin MA, Rhaleb NE, Yang XP, Carretero OA

Hypertension (Dallas, Tex. : 1979)22 Mar 2004Cited by 108 (Europe PMC)

PMID15037553 (opens in a new tab)PMCIDPMC4677773 (opens in a new tab)DOI10.1161/01.hyp.0000126172.01673.84 (opens in a new tab)PepBankPUB-15037553
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueMechanism

    In kidney cortex homogenates with added thymosin-beta4, Ac-SDKP was generated in a time-dependent manner.

    In plain wordsIn lab tests on kidney tissue, adding thymosin-beta4 led to the peptide Ac-SDKP forming over time.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseAc-SDKP generation from exogenous thymosin-beta4
    Study

    ratn: not reported in source

    kidney cortex homogenates
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    Ac-SDKP was generated in a time-dependent manner in the presence of exogenous thymosin-beta4
    1 context sentence
    Summary · context
    We investigated in vitro and in vivo production of Ac-SDKP.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueMechanism

    In kidney cortex homogenates, prolyl oligopeptidase inhibitors significantly reduced Ac-SDKP generation from thymosin-beta4.

    In plain wordsIn lab tests on kidney tissue, prolyl oligopeptidase inhibitors reduced how much Ac-SDKP formed from thymosin-beta4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseInhibition of Ac-SDKP generation by prolyl oligopeptidase inhibitors
    Study

    ratn: not reported in source

    kidney cortex homogenates
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    this generation was significantly inhibited by several POP inhibitors (POPi), Z-prolyl-prolinal, Fmoc-prolyl-pyrrolidine-2-nitrile, and S17092.
    1 context sentence
    Summary · context
    We investigated in vitro and in vivo production of Ac-SDKP.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.